

**FOOD AND DRUG ADMINISTRATION (FDA)**  
Center for Drug Evaluation and Research (CDER)

***Oncologic Drugs Advisory Committee (ODAC) Meeting***  
April 30, 2026

**MEETING ROSTER**

---

---

**ACTING DESIGNATED FEDERAL OFFICER (Non-Voting)**

**Joyce Frimpong, PharmD**

Division of Advisory Committee and Consultant Management  
Office of Executive Programs, CDER, FDA

**ONCOLOGIC DRUGS ADVISORY COMMITTEE MEMBERS (Voting)**

**Toni K. Choueiri, MD**

Director, Lank Center for Genitourinary Oncology  
Professor, Harvard Medical School  
Dana-Farber Cancer Institute  
Boston, Massachusetts

**William J. Gradishar, MD**

*(via video conferencing platform)*  
Betsy Bramsen Professor of Breast Oncology and  
Professor of Medicine  
Deputy Director, Clinical Network  
Director, Maggie Daley Center for Women's Cancer  
Care  
Robert H. Lurie Comprehensive Cancer Center  
Feinberg School of Medicine at  
Northwestern University  
Chicago, Illinois

**Neil Vasan, MD, PhD**

*(Acting Chairperson)*  
Assistant Professor  
Director, Breast Cancer Translational Research  
Department of Medicine, NYU Grossman School of  
Medicine  
Perlmutter Cancer Center, NYU Langone Health  
New York, New York

**ONCOLOGIC DRUGS ADVISORY COMMITTEE MEMBERS (Non-Voting)**

**Tara L. Frenkl, MD, MPH**

Senior Vice President, Head of Global Medical  
Strategy and Evidence Generation  
Bayer Pharmaceuticals  
Whippany, New Jersey

FOOD AND DRUG ADMINISTRATION (FDA)  
Center for Drug Evaluation and Research (CDER)

*Oncologic Drugs Advisory Committee (ODAC) Meeting*  
April 30, 2026

MEETING ROSTER (cont.)

---

---

TEMPORARY MEMBERS (Voting)

**Karla V. Ballman, PhD, FASCO**

Professor, Biostatistics  
Division Chair, Division of Clinical Trials &  
Biostatistics  
Mayo Clinic  
Rochester, Minnesota

**Sarah Colonna, MD, MSCI**

*(Morning Session Only)*  
Associate Professor, Medical Oncology,  
Interim Co-Division Chief, Medical Oncology,  
Medical Director of FCAC/Genetics  
Huntsman Cancer Institute/University of Utah  
Director, Comprehensive Genetics Services,  
Veterans Affairs (VA) National Oncology Program  
Salt Lake City, Utah

**Natalie Compagni- Porits, PsyD, MFT**

*(Patient Representative; Morning Session Only)*  
Sonoma, California

**Paul T. Conway**

*(Patient Representative)*  
*Afternoon Session Only; via video conferencing*  
*platform)*  
Falls Church, Virginia

**Lori E. Dodd, PhD**

*(Morning Session Only)*  
Branch Chief  
Clinical Trials Research and Statistics Branch  
Office of Biostatistics Research  
National Institute of Allergy and Infectious  
Diseases  
Bethesda, Maryland

**Franklin Huang, MD, PhD**

*(Afternoon Session Only)*  
Associate Professor  
Departments of Medicine and Urology  
University of California San Francisco  
Staff Physician, San Francisco Veterans Affairs  
Medical Center (VAMC)  
Scientific Director, Sierra Pacific Precision Oncology  
Clinical Research Center  
San Francisco, California

**Fatima Karzai, MD**

*(Afternoon Session Only)*  
Senior Clinician, Genitourinary Malignancies  
Branch  
Deputy Clinical Director, Center for Cancer  
Research, National Cancer Institute (NCI)  
National Institutes of Health (NIH)

**Michael J. Kelley, MD**

*(Morning Session Only)*  
Executive Director  
National Oncology Program  
Specialty Care Services, Veterans Health  
Administration  
Chief, Hematology/Oncology  
Durham VAMC  
Professor of Medicine  
Duke University Medical Center  
Durham, North Carolina

**FOOD AND DRUG ADMINISTRATION (FDA)**  
Center for Drug Evaluation and Research (CDER)

***Oncologic Drugs Advisory Committee (ODAC) Meeting***  
April 30, 2026

**MEETING ROSTER (cont.)**

---

---

**Stanely Lipkowitz, MD, PhD**

*(Morning Session Only)*

Chief, Women's Malignancies Branch  
Deputy Director, Center for Cancer Research  
NCI, NIH  
Bethesda, Maryland

**Brian Rini, MD**

*(Afternoon Session Only, via video conferencing platform)*

Professor of Medicine  
Vanderbilt Ingram Cancer Center  
Department of Hematology/Oncology  
Vanderbilt University Medical Center  
Nashville, Tennessee

**Kyle Robinson, MD**

*(Afternoon Session Only)*

Staff Physician  
Corporal Michael J. Crescenz VA Medical Center  
Associate Professor of Clinical Medicine  
Division of Hematology-Oncology  
University of Pennsylvania Perelman School of Medicine  
Philadelphia, Pennsylvania

**Aihua Edward Yen, MD**

*(Afternoon Session Only)*

Assistant Professor  
Department of Medicine, Section of Hematology/  
Oncology  
Baylor College of Medicine  
Genitourinary Medical Oncologist  
Dan L Duncan Cancer Center  
Houston VA Medical Center  
Houston, Texas

**FDA PARTICIPANTS (Non-Voting)**

**R. Angelo de Claro, MD**

Director (Acting)  
Oncology Center for Excellence, FDA

Director (Acting), Office of Oncologic Diseases  
(OOD), CDER, FDA

**Laleh Amiri-Kordestani, MD**

Director  
Division of Oncology 1 (DO1)  
OOD, Office of New Drugs (OND), CDER, FDA

**Daniel Suzman, MD**

*(Afternoon Session Only)*

Deputy Director  
DO1, OOD, OND, CDER, FDA

**Mirat Shah, MD**

*(Morning Session Only)*

Clinical Team Leader  
DO1, OOD, OND, CDER, FDA

**Elaine Chang, MD**

*(Afternoon Session Only)*

Clinical Team Leader  
DO1, OOD, OND, CDER, FDA

**Joshua Donaldson, MD, PhD**

*(Morning Session Only)*

Clinical Reviewer  
DO1, OOD, OND, CDER, FDA

**Suparna Wedam, MD**

*(Morning Session Only)*

Clinical Reviewer  
DO1, OOD, OND, CDER, FDA

**Daniel Lee, MD, PhD**

*(Afternoon Session Only)*

Clinical Reviewer  
DO1, OOD, OND, CDER, FDA

**FOOD AND DRUG ADMINISTRATION (FDA)**  
Center for Drug Evaluation and Research (CDER)

***Oncologic Drugs Advisory Committee (ODAC) Meeting***  
April 30, 2026

**MEETING ROSTER (cont.)**

---

---

**Daeyoung Lim, PhD**

*(Morning Session Only)*

Statistical Reviewer

Division of Biometrics V

Office of Biostatistics

Office of Translational Sciences

CDER, FDA